Zydus Cadila has received the final approval from the USFI)A to market Acetazolamide for
Injection USP (US RLD Diamox for Injection), 500 mg per single-dose vial. It will be
manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
Acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluid secretion (e.g. some types of glaucoma), treatment of certain convulsive disorders (e. g. epilepsy) and promotion of diuresis in instances of abnormal fluid retention (e.g. cardiac edema).
The group now has 262 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
